AC Immune (NASDAQ:ACIU) Lowered to “Hold” Rating by StockNews.com

StockNews.com downgraded shares of AC Immune (NASDAQ:ACIU) from a buy rating to a hold rating in a research report sent to investors on Monday.

Separately, HC Wainwright cut their target price on shares of AC Immune from $16.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, May 1st.

AC Immune Stock Up 2.5 %

NASDAQ:ACIU opened at $1.66 on Monday. AC Immune has a twelve month low of $1.43 and a twelve month high of $4.98. The firm has a market capitalization of $166.68 million, a price-to-earnings ratio of -3.61 and a beta of 1.62. The stock’s 50 day moving average price is $1.86 and its two-hundred day moving average price is $2.54.

AC Immune (NASDAQ:ACIU) last issued its earnings results on Wednesday, April 30th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. The firm had revenue of $1.12 million for the quarter, compared to analyst estimates of $1.99 million. As a group, analysts anticipate that AC Immune will post -0.62 earnings per share for the current year.

Hedge Funds Weigh In On AC Immune

Several large investors have recently modified their holdings of the stock. Renaissance Technologies LLC grew its stake in AC Immune by 14.6% in the 4th quarter. Renaissance Technologies LLC now owns 740,198 shares of the company’s stock valued at $1,999,000 after buying an additional 94,191 shares during the last quarter. RPO LLC bought a new stake in shares of AC Immune during the fourth quarter worth approximately $51,000. Cantor Fitzgerald L. P. acquired a new position in shares of AC Immune in the fourth quarter valued at approximately $68,000. Quinn Opportunity Partners LLC bought a new position in shares of AC Immune during the fourth quarter worth approximately $27,000. Finally, Boothbay Fund Management LLC acquired a new stake in AC Immune during the 4th quarter worth approximately $38,000. 51.36% of the stock is owned by institutional investors.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.